Press Releases

Indivior Announces First Half and Second Quarter 2020 Results

Period to June 30thQ2 2020 $mQ2 2019 $m% ∆ Actual FX% ∆ Constant FXH1 2020 $mH1 2019 $m% ∆ Actual FX% ∆ Constant FX
Net Revenue150215-30-30303454-33-33
Operating Profit/(Loss)2588-72-71(165)163NMNM
Net Income/(Loss)1875-76-75(145)141NMNM
EPS (cents per share)210-80-75(20)19NMNM
Adj. Operating Profit*2489-73-7226191-86-87
Adj. Net Income*1776-78-7714165-92-92
Adj. EPS*210-80-77223-91-92


*Adjusted (Adj.) basis excludes the impact of exceptional items as referenced in Notes 3 and 4. NM: Not Meaningful.

Comment by Mark Crossley, CEO of Indivior PLC
“I am proud of the Group’s resilient performance through this unprecedented period brought about by the COVID-19 pandemic. Considering this backdrop, our first-half results were solid. We maintained a good cash buffer and we did so while helping to ensure the safety and wellbeing of our employees. I am particularly encouraged by the performance of SUBLOCADE® (buprenorphine extended-release) Injection through this period, as Q2 net revenue of $29m was unchanged versus Q1’s level. Furthermore, we came to a satisfactory agreement with the DOJ (subject to judicial approval) that allows us to focus our resources on pursuing our Vision and patient-focused growth strategy. In the short term, we continue to be impacted by the industry-wide reduction in new patient starts in the U.S. However, looking to the future, I am confident that our novel depot technologies, SUBLOCADE® and PERSERIS® (risperidone) extended release injection, have the power to transform lives and to drive a new era of growth.”


Read full report here.